Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Thetis Pharma Awarded Grant to Develop Therapy for IBD | Contract Pharma

What are you searching for?

Sign in
Breaking News

Thetis Pharma Awarded Grant to Develop Therapy for IBD

The $2.3 million is for TP-317, which has the potential to be a first-in-class oral, immuno-resolving alternative

By: Betsy Louda

, Contract Pharma

Thetis Pharmaceuticals, a developer of immuno-resolving therapies for treatment of inflammatory bowel disease, has received a Fast-Track Small Business Innovation Research Grant from the National Institutes of Health. The award provides up to $2.3 million to support development of Thetis’ TP-317 candidate as oral therapy for treatment of ulcerative colitis.

 

“TP-317 offers a fundamentally new approach to IBD treatment based on active resolution of inflammation and the promotion of tissue regeneration without suppressing the immune system. The grant will support the advancement of this promising, potential new therapy into the clinic.” said Gary Mathias, co-founder and chief executive officer at Thetis.

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters